top of page
News
Chat
Analysis
Education
About
Pricing
BPIQ API
BPIQ Blog
UROV's Vibegron Imminent Phase 3 Readout In Overactive Bladder Has a Good Chance of Success
Based on robust Ph2B and Ph3 (Japan) data in prior trials with similar design, it appears highly likely that UROV's Vibegron will meet...
Mar 14, 2019
1 min read
Jump start your biotech due diligence
Get started →
Our platform helps you uncover your next biotech investment opportunity
bottom of page
